Resumen
Introducción: la paralisis periodica tirotóxica (PPT) es una complicación poco común del hipertiroidismo, corresponde la causa más frecuente de parálisis aguda flácida del adulto.
Material y métodos: se realizó un estudio observacional retrospectivo en 2 hospitales referenciales del seguro social en Lima-Perú, que incluyo a 22 pacientes (21 hombres, 1 mujer) diagnosticados con PPT durante el periodo 2014-2021.
Resultados: la edad promedio al diagnóstico fue de 35.77 ± 9.6 años, todos de raza mestiza, en 82% de los pacientes el diagnostico de hipertiroidismo fue establecido a partir de esta entidad, la etiología en el 95% fue autoinmune (enfermedad de Graves-Basedow) excepto uno cuya etiología fue bocio multinodular tóxico. El evento desencadenante reportado en 54% de pacientes fue la ingesta de comida copiosa alta en carbohidratos, seguido del ejercicio (27%), el horario más frecuente de presentación fue durante la mañana ( 41% de los casos), el patrón de debilidad principal comprometió miembros inferiores(45% paraplejia, 18% paraparesia), solo 36% fue diagnosticado de PPT en su primer episodio de debilidad motora.
Conclusiones: consideramos que se debe sospechar esta condición en cualquier paciente varón joven de cualquier etnia con debilidad muscular aguda, asociado a niveles séricos bajos de potasio y síntomas de tirotoxicosis, aunque su ausencia no debe descartar el diagnostico. Se debe identificar en lo posible el factor precipitante e instaurar terapia inicial con propanolol con o sin reemplazo de potasio endovenoso u oral, con monitoreo posterior adecuado que minimice el riesgo de hiperpotasemia de rebote.
Abstract
Background: Thyrotoxic Periodic Paralysis (PPT) is an uncommon complication of hyperthyroidism, it is the most frequent cause of acute flaccid paralysis in adults.
Material and methods: A retrospective observational study was carried out in 2 reference hospitals of the social security in Lima-Peru, which included 22 patients diagnosed with PPT during the period 2014-2021.
Results: the average age at diagnosis was 35.77 ± 9.6 years, all of mixed race, in 82% of the patients the diagnosis of hyperthyroidism was established from this entity, the etiology in 95% was autoimmune (Graves-Basedow) except for one whose etiology was toxic multinodular goiter. The triggering event reported in 54% of patients was the intake of copious food high in carbohydrates, followed by exercise (27%), the most frequent presentation time was during the morning (41% of the cases), the main weakness pattern compromised lower limbs (45% paraplegia, 18% paraparesis), only 36% were diagnosed with PPT in their first episode of motor weakness.
Conclusions: We consider that this condition should be suspected in any young male patient of any ethnicity with acute muscle weakness, associated with low serum potassium levels and symptoms of thyrotoxicosis, although its absence should not rule out the diagnosis. The precipitating factor should be identified as much as possible and initial therapy with propanolol with or without intravenous or oral potassium replacement should be established, with adequate subsequent monitoring to minimize the risk of rebound hyperkalemia.
Díaz da Silva MR, Chiamolera MI, Kasamatsu TS, Cerutti JM, Maciel RMB. Paralisia periódica hipocalêmica tirotóxica, uma urgência endócrina: revisão do quadro clínico e genético de 25 pacientes. Arq Bras Endocrinol Metabol. 2004;48(1):196- 215. DOI:10.1590/S0004-27302004000100022.
Calipuy Gálvez JM, Suárez Ale H. Parálisis periódica tirotóxica hipopotasémica. Rev Soc Peru Med Interna. 2010; 23(4):163-6. DOI: 10.36393/spmi.v23i4.388.
Balakrishnan RK, Chandran SR, Thirumalnesan G, Doraisamy N. Thyrotoxic periodic paralysis. Indian J Endocrinol Metab. 2011;15(Suppl 2):147. DOI: 10.4103/2230-8210.83360.
Lin SH. Thyrotoxic Periodic Paralysis. Mayo Clin Proc. 2005; 80(1):99-105. DOI: 10.1016/S0025-6196(11)62965-0.
Maciel RMB, Lindsey SC, Dias Da Silva MR. Novel etiopatho-physiological aspects of thyrotoxic periodic paralysis. Nat Rev Endocrinol. 2011;7:657-67. DOI: 10.1038/nrendo.2011.58.
Meseeha M, Parsamehr B, Kissell K, Attia M. Thyrotoxic periodic paralysis: a case study and review of the literature. J Community Hosp Intern Med Perspect. 2017;7(2):103-6. DOI: 10.1080/20009666.2017.1316906.
Hsieh CH, Kuo SW, Pei D, Hung YJ, Chyi-Fan S, Wu LI, et al. Thyrotoxic periodic paralysis: an overview. Ann Saudi Med. 2004;24(6):418-22. DOI: 10.5144/0256-4947.2004.418.
Neki NS. Hyperthyroid hypokalemic periodic paralysis. Pak J Med Sci. 2016;32(4):1051-2. DOI: 10.12669/pjms.324.11006.
Chang CC, Cheng CJ, Sung CC, Chiueh TS, Lee CH, Chau T, et al. A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: Focus on symptomatology and precipitants. Eur J Endocrinol. 2013;169(5):529-36. DOI: 10.1530/EJE-13-0381.
Iqbal QZ, Niazi M, Zia Z, Sattar SBA. A Literature Review on Thyrotoxic Periodic Paralysis. Cureus. 2020;12(8):10-2. DOI: 10.7759/cureus.10108.
Naqi M, Bhatt VR, Pant S, Shrestha R, Tadros M, Murukutla S, et al. A 20-year-old Chinese man with recurrent hypokalemic periodic paralysis and delayed diagnosis. BMJ Case Rep. 2012;bcr0120125541. DOI:10.1136/bcr.01.2012.5541.
Yao Y, Fan L, Zhang X, Xiao Z, Long Y, Tian H. Episodes of paralysis in Chinese men with thyrotoxic periodic paralysis are associated with elevated serum testosterone. Thyroid. 2013;23(4):420-7. DOI: 10.1089/thy.2011.0493.
Sáenz-Bustamante S, Yovera-Aldana M, Churampi-López M, Jáuregui-Macedo N, Delgado-Rojas M, Liviac-Cabrera D, et al. Características clínico-laboratoriales de pacientes con parálisis periódica tirotóxica en el Hospital Nacional Edgardo Rebagliati Martins, 2011-2014. An Fac med. 2014;75(3):280. DOI: 10.15381/anales.v75i3.9789.
Al-Zubeidi H, Demeterco C, Jones KL. Thyrotoxic, hypokalemic periodic paralysis (THPP) in adolescents. J Pediatr Endocrinol Metab. 2015;28(1-2):157-61. DOI: 10.1515/ jpem-2014-0016.
Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Archives of Internal Medicine. 1999;159(6): 601-6. DOI: 10.1001/archinte.159.6.601.
Ozbakir O, Dogukan A, Kelestimur F. The prevalence of thyroid dysfunction among elderly subjects in an endemic goiter area of Central Anatolia. Endocr J. 1995;42(5): 713-6. DOI: 10.1507/endocrj.42.713.
Nakamura S, Sugimoto M, Kosaka J, Watanabe H, Shima H, Kawahira S. Silent thyroiditis with thyroid-stimulationblocking antibodies (TSBAb). Jpn J Med. 1990;29(6):623-7. DOI: 10.2169/internalmedicine1962.29.623.
Cesur M, Bayram F, Temel MA, Ozkaya M, Kocer A, Ertorer ME, et al. Thyrotoxic hypokalaemic periodic paralysis in a Turkish population: three new case reports and analysis of the case series. Clin Endocrinol (Oxf). 2008;68(1):143-52. DOI: 10.1111/j.1365-2265.2007.03014.x.
Chan A, Shinde R, Chow CC, Cockram CS, Swaminathan R. Hyperinsulinaemia and Na+, K+ -ATPase activity in thyrotoxic periodic paralysis. Clin Endocrinol (Oxf). 1994;41(2):213-6. DOI: 10.1111/j.1365-2265.1994.tb02532.x.
Levey GS, Klein I. Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. Am J Med. 1990;88(6):642-6. DOI: 10.1016/0002-9343(90)90533-j.
Lee KO, Taylor EA, Oh VM, Cheah JS, Aw SE. Hyperinsulinaemia in thyrotoxic hypokalaemic periodic paralysis. Lancet. 1991;337(8749):1063-4. DOI: 10.1016/0140-6736(91)91710-c.
Blanco G, Mercer RW. Isoenzymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Am J Physiol. 1998;275(5):F633-F650. DOI: 10.1152/ ajprenal.1998.275.5.F633.
Wu CC, Chau T, Chang CJ, Lin SH. An unrecognized cause of paralysis in ED: thyrotoxic normokalemic periodic paralysis. Am J Emerg Med. 2003;21(1): 71-3. DOI: 10.1053/ ajem.2003.50005.
Mehta SR, Verma A, Malhotra H, Mehta S. Normokalaemic periodic paralysis as the presenting manifestation of hyperthyroidism. J Assoc Physicians India. 1990;38(49):296-7.
Shifrin A. Endocrine Emergencies. 1st ed. Philadelphia: Elsevier; 2021.
Rone JK, Brietzke SA. Euthyroid thyrotoxic periodic paralysis. Mil Med. 1991;156(8):434-6.
Correia M, Darocki M, Hirashima ET. Changing management guidelines in thyrotoxic hypokalemic periodic paralysis. J Emerg Med. 2018;55(2):252-6. DOI: 10.1016/j. jemermed.2018.04.063.
Falhammar H, Thorén M, Calissendorff J. Thyrotoxic periodic paralysis: clinical and molecular aspects. Endocrine. 2013; 43:274-84. DOI: 10.1007/s12020-012-9777-x.
Tassone H, Moulin A, Henderson SO. The pitfalls of potassium replacement in thyrotoxic periodic paralysis: a case report and review of the literature. J Emerg Med. 2004;26(2):157-61. DOI: 10.1016/j.jemermed.2003.05.004.
Griggs RC, Resnick J, Engel WK. Intravenous treatment of hypokalemic periodic paralysis. Arch Neurol. 1983;40(9):539- 40. DOI: 10.1001/archneur.1983.04050080039005.